99 results about "Diabetes model" patented technology

The present invention is process of extracting 1-deoxy nojirimycin (DNJ) from mulberry leaf. Mulberry leaf extract is treated with inorganic acid, cooled to eliminate impurity and column chromatographically separated to obtain DNJ. Animal experiment of mouse shows that the mulberry leaf extract has obvious blood sugar reducing effect, so that the present invention may be used in preparing blood sugar reducing health product. The present invention has low preparation cost, and is suitable for industrial production.

The application of Magnolia officinalis preparation for the production of medicaments for treating diabetes and obesity belongs to the field of medicinal application. The Magnolia officinalis preparation is extracted from Magnolia officinalis by soaking in ethanol with magnolol and honokiol as main ingredients. The preparation has effects of in-vitro inhibiting the activity of protein-tyrosine phosphatase 1B (PTP1B) and reducing blood sugar level in rat model of type 2 diabetes. The preparation can be made into powder, pill, capsule, tablet, oral liquid and injection. It can be used for treating diabetes, obesity, and diseases related to PTP1B.

The invention provides application of lentinan in preparing medicines, healthcare products and food in treating or preventing diseases caused by enteric flora disturbance. The applicant of the invention adopts high-fat feed to induce a mouse obesity type-II diabetes model to observe the influence of polysaccharide in traditional Chinese medicines on lipid metabolism of mice through enteric florae, and by adopting the lentinan, enteric flora disturbance caused by diet can be adjusted, constitution of enteric florae can be remarkably improved, and the unbalance enteric florae in bodies can be recovered, so that the blood fat and the blood sugar indexes of obesity caused by enteric flora disturbance caused by diet can be adjusted, the content of triglyceride in blood plasma can be remarkably reduced, and the content of cholesterol, low density lipoprotein and free fatty acid can be reduced.

The invention belongs to the technical field of biological pharmacy, and in particular relates to suppressive activity detection of tetrahydroxy norathyriol on protein-tyrosine-phosphatase (PTP) 1B, improvement of resistance function of insulin and accpication in medicament for PTP1B related diseases. Proved by in vitro enzyme suppression experiments, the invention testifies that mango aglycone is the competitive suppressant of restructuring humanized PTP1B with IC50 value being 9.2 mu m; mango aglycone can ensure the sensitivity of C57BL / 6 normal mouse and ob / ob diabetes model mouse on insulin to be obviously improved, and reduce blood sugar of experimental animals, which suggests that mango aglycone is a novel suppressant of PTP1B, and can be taken as potential lead compound to be applied in preparing medicament for curing insulin resistance related diabetes, obesity and other metabolic syndrome, tumor and other PTP1B related diseases.

The present invention relates to an application of acetylcholinesterase inhibitor for curing diabetes. The described inhibitor includes all the compounds which can inhibit acetylcholinesterase activity and have the action for curing diabetes. The invented experimental results show that these inhibitors have the actions of inhibiting beta-cell death and reducing blood sugar concentration of diabetic model mouse, and can effectively cure or improve diabetes symptom.

The invention belongs to the technical field of biology and particularly discloses selenium-rich bifidobacterium longum as well as a preparation method and application thereof. The selenium-rich bifidobacterium longum prepared by virtue of the preparation method can be applied to the preparation drugs or foods for delaying the progress of diabetes mellitus and particularly can be applied to the preparation of the drugs or the foods for improving the physical signs and metabolism conditions of diabetes mellitus, the insulin signal pathways of a diabetes mellitus model, the pathological change of livers, pancreas and kidneys of patients with diabetes mellitus and the levels of serum creatinine and blood urea nitrogen of diabetes mellitus and preventing renal complications or renal function damage of diabetes mellitus.

The invention relates to a benzimidazole derivative 2-m-phenylaminobenzimidazolyl-1H-pyrazolyl-3-formamide of which the structural formula is disclosed in the specification. The benzimidazole derivative can promote growth of microzyme, enhance the metabolic activity of the microzyme, obviously lower the plasma triglyceride, total cholesterol and high density lipoprotein of a C57 BL / 6J mouse which is fed by high-fat feed for a long time, lower the contractive pressure and diastolic pressure of the model mouse, lower the fasting blood-glucose of the model mouse, improve the sugar tolerance of the mouse, influence the expression of SIRT1 and related genes (FOXO1, P53, PPARgamma and PGC-1alpha), and obviously improve the metabolism of glucose and fat; and therefore, the benzimidazole derivative can be used for preparing medicines for preventing and treating diabetes and complications thereof.

The invention is suitable for the field of medicine and provides a method for establishing a diabetes-inducing model. The method comprises the following steps of feeding male monkeys with high-fat feed, wherein the male monkeys account for 5 / 6 of the total quantity of experimental animals, and are 7-20 years old, and the high-fat feed comprises the following main components: 18 percent of protein, 60 percent of saccharides and 22 percent of fat; feeding male monkeys with standard feed, wherein the male monkeys account for 1 / 6 of the total quantity of the experimental animals, and are 4-10 years old, and the standard feed comprises the following main components: 18 percent of protein, 69 percent of saccharides and 3 percent of fat. According to the method for establishing the diabetes-inducing model provided by the invention, by establishing the model for inducing diabetes by long-term diet, the problems that the long-term slow process of human diabetes development cannot be really simulated very well by drug modeling, and the whole organism is changed by the fact that the long-term slow process cannot be really simulated very well can be solved, and the scientificity is stronger.

The invention relates to the technical field of biology, in particular to application of polysaccharide. The invention provides the application of lentinan in preparation of healthcare food capable of improving the abundance of beneficial bacteria and reducing the abundance of harmful bacteria in intestinal florae. An applicant for the invention observes the influence of the lentinan on lipid metabolism in mice through the intestinal florae by inducing obesity type-2 diabetic models of the mice through high-fat diet; the lentinan provided by the invention can regulate intestinal flora disturbance caused by diet, and can obviously change the proportion of the harmful bacteria in the intestinal florae and make unbalanced intestinal florae in vivo to trend to be normal so as to regulate the blood fat and blood sugar indicators of obesity caused by the intestinal flora disturbance due to the diet; the content of triglyceride in blood plasma can be obviously reduced; the content of cholesterol, low-density lipoprotein and free fatty acid can be reduced.

The invention provides a diabetes primate model construction method. The method comprises the following steps of injecting streptozotocin into cynomolgus monkeys according to a small-dose progressiveincrease method, feeding the cynomolgus monkeys with high-sugar and high-fat feed at the same time, and after injecting the streptozotocin into the cynomolgus monkeys and feeding the cynomolgus monkeys with the high-sugar and high-fat feed for a period of time, increasing night illumination to induce the cynomolgus monkeys to become diabetes models. The diabetic monkey model is successfully established by adopting the method for 1.5-6 months, the model has the core characteristics of insulin resistance and hyperglycemia, the duration of hyperglycemia is long, and the hyperglycemia is not reduced after more than 200 days. The animal model established by the invention can be used in animal experiments with longer duration, and can be sold as a mature animal model to generate economic benefits.

The invention belongs to the field of Chinese herbal medicine substance activity and medicine research and development thereof and relates to a Chinese herbal medicine substance, in particular to a composition which has blood fat and blood sugar reducing activity and is prepared from Chinese herbal medicine substances, a preparing method and application of the composition, and an associated Chinese herbal or natural medicine compound (such as a Chinese herbal compound prepared from stevia rebaudiana, lotus leaves, panax notoginseng, hawthorn fruits and the like). The chemical architecture of the Chinese herbal medicine substance composition is mainly prepared from phenols, alkaloids, terpenes, amino acids and the like, and can be obtained through solvent (such as diluted alcohol) extraction from the compound or separation and enrichment of macroporous resin; tests with a hyperlipidemia model and a diabetes model of mice proves that the composition prepared from the Chinese herbal medicine substances has remarkable blood fat and blood sugar reducing activity. The composition prepared from the Chinese herbal medicine substances and the associated compound of the composition can be used for medicine and health products.

The present invention provides a non-human mammal deficient in the expression of the SLC-1 gene, having the characteristics of (1) a lower blood insulin level in glucose tolerance test, (2) increased insulin sensitivity, (3) higher resistance to obesity even on high fat diet, (4) a smaller white fat cell size, and (5) accentuated lipolysis, compared with the corresponding wild-type animal, or a portion of the body thereof. Also provided is an obesity and / or type II diabetes model non-human mammal that is deficient in the expression of the SLC-1 gene, having the characteristics of (1) elevated expression of adiponectin, (2) delayed onset of hyperglycemia, (3) a lower blood glycohemoglobin level, and (4) accentuated energy consumption, compared with the corresponding obesity and / or type II diabetes model non-human mammal wherein the expression of the gene is normal, or a portion of the body thereof.

The invention provides a microvalve-based dual-detection microfluidic chip and a method for constructing a diabetes model. The chip is composed of three layers of PDMS, the upper layer is the liquid circuit layer, the lower layer is the air circuit control layer, and the middle of the upper and lower layers is the PDMS membrane. A method for constructing a diabetes model based on a microvalve-based dual-detection microfluidic chip. A single nematode is added to the entrance of the worm and the drug, and the single worm is introduced into the nematode fixation and culture room. During fluorescence imaging, the air pressure is used to deform the PDMS membrane, and the worm body is compressed. It is fixed and imaged on the side wall of the sampling channel; material exchange is performed three times a day to add fresh food and apply glucose or drug stimulation to discharge nematode metabolic waste. The invention adopts channel design, which is simple to operate and easy to realize material exchange, which is beneficial to the long-term cultivation of nematodes; the method of fixing nematodes adopts the method of membrane deformation, which is safe and harmless to the nematodes, and can be used for long-term cultivation, movement and imaging of a single nematode. detection.

The invention relates to a benzothiazole derivative, a preparation method and an application thereof, wherein the benzothiazole derivative is 2-m-aniline benzothiazole-1H-pyrazole-3-formamide, and the structural formula of the benzothiazole derivative is shown in the description. The benzothiazole derivative disclosed by the invention can accelerate the growth of saccharomycetes, strengthen the metabolic activity of the saccharomycetes, obviously reduce the plasma triglyceride, the total cholesterol and the high-density lipoprotein of C57 BL / 6J mice fed with high-fat feedstuff, reduce the systolic pressure and the diastolic pressure of model mice, reduce the fasting blood glucose of the model mice, improve the sugar tolerance of the mice, affect the expression of SIRT1 and relevant genes (FOXO1, P53, PPAB gamma and PGC-1 alpha), and obviously improve the sugar and fat metabolism of diabetic model mice. Therefore, the benzothiazole derivative can be applied to preparing medicines for preventing and treating diabetes mellitus and complications of the diabetes mellitus.

Provided is a method for building a chronic wound animal experiment model. The method for building the chronic wound animal experiment model comprises the following steps of (1) selecting a clean experimental animal or building a type II diabetes model in an induction mode, then, shaving off long hair on the back of the experimental animal with an electric shaver, carrying out unhairing with a 10% sodium sulphide solution, making a mark in the center of the nape, making longitudinal cuts in the two sides of the mark, carrying out opposite side suture after hemostasis is carried out, forming a skin-tube-shaped structure, and (2) removing suture lines after 24 hours, opening the skin-tube-shaped structure, suturing the skin back, and making a wound on the original skin-tube-shaped structure. The method for building the chronic wound animal experiment model has the advantages that a modeling method is simple, the model is stable, repeatability is high, and the area is controllable.

The invention relates to the technical field of food processing and discloses noodles capable of reducing blood sugar and regulating blood lipid and a preparation method. The noodles are prepared from raw materials in parts by weight as follows: 100 parts of high gluten wheat flour, 1-9 parts of tartary buckwheat flour, 1-9 parts of yam flour, 10-30 parts of mulberry leaves, 10-25 parts of radix puerariae and 10-30 parts of bitter gourds. The active ingredients of the mulberry leaves, the radix puerariae, the bitter gourds and the like are extracted and mixed with the high gluten wheat flour, the tartary buckwheat flour and the yam flour for preparation of the noodles. Animal experiments and feeding trials prove that the noodles have significant effects of reducing blood sugar and regulating blood lipid on a diabetes model mouse and can effectively control postprandial blood sugar rise of diabetics and obviously improve the oxidative stress resistant level. The noodles can be used as safe staple food of the diabetics to control postprandial blood sugar rise and improve the life quality of the diabetics and can also be used as healthcare food for preventing diabetes to be eaten for a long term.

The invention provides a Chinese herbal medicine compound preparation for treating diabetes and preparation and application of the Chinese herbal medicine compound preparation. The Chinese herbal medicine compound preparation for treating diabetes is characterized by being prepared from okra and bitter gourds. The preparing method of the Chinese herbal medicine compound preparation for treating diabetes comprises the steps that firstly, okra and bitter gourds are washed clean, sliced, dried in the sun and ground into powder respectively; secondly, the okra powder and the bitter gourd powder obtained in the first step are mixed according to a proportion and boiled with water three times, filtering is carried out after each time of water boiling, water boiling solutions are mixed, evaporated, condensed and dried, and dry extract is obtained; thirdly, the dry extract is ground into powder, evenly mixed and granulated, and the Chinese herbal medicine compound preparation for treating diabetes is obtained. According to the Chinese herbal medicine compound preparation for treating diabetes and preparation and application of the Chinese herbal medicine compound preparation, the influence of okra and bitter gourd water extract on the blood glucose of mice in a diabetes model is studied, and the blood glucose reducing effect of okra and a compound thereof is preliminarily discussed.

The invention discloses a method for establishing an experimental model of a diabetic foot ulcer big mouse infected by staphylococcus aureus. The method includes the following steps that after the big mouse is fed on high-fat diet for eight weeks, streptozotocin is injected, and a diabetic model is manufactured. After the diabetic model is stabilized, II-degree scalding is performed on the skin of the big mouse, and after three days, subcutaneous injection of suspension liquid with staphylococcus aureus as the bacterial strain is performed in each ulcer position. In addition, the invention further discloses a kit for establishing the experimental model of the diabetic foot ulcer big mouse infected by the staphylococcus aureus, wherein the kit comprises the staphylococcus aureus suspension liquid. The diabetic foot ulcer experimental animal model detects variation of biochemical indexes after pharmacological intervention, and a result shows that the model has the infection features of diabetic foot ulcer and concurrent gram-positive bacteria. The model has the advantages of being short in ulcer wound surface healing time, sensitive to drug reaction and the like.

The invention relates to the technical field of biology, and especially relates to a purpose of ganoderan in preparation of health food for regulating flora in intestinal tract. The invention provides the purpose of ganoderan in preparation of health food capable of increasing beneficial bacteria abundance in flora of intestinal tract and reducing harmful bacterium abundance. The applicant of the invention adopts high-fat feed to induce a mouse obesity type-II diabetes model to observe the influence of ganoderan on lipid metabolism of mice through enteric florae, and by adopting the ganoderan, enteric flora disturbance caused by diet can be adjusted, constitution of enteric florae can be remarkably improved, and the unbalance enteric florae in bodies can be recovered, so that the blood fat and the blood sugar indexes of obesity caused by enteric flora disturbance caused by diet can be adjusted, the content of triglyceride in blood plasma can be remarkably reduced, and the content of cholesterol, low density lipoprotein and free fatty acid can be reduced.

The invention relates to the medicinal application of NAM, specifically to application of NAM to preparation of drugs used for preventing and treating diabetic nephropathy and regulating blood pressure, belonging to the field of compounds. The experimental results of intervention of NAM in type 2 diabetes model mice prove NAM has obvious protective effect on diabetic kidneys and can alleviate therenal fibrosis, inflammations and oxidative stress in diabetic mice, and the protection effect is achieved independent of blood sugar reduction and weight improvement. Further, NAM can be used for preparing drugs for preventing and treating diabetic nephropathy and regulating blood pressure. The application of NAM in the invention provides a novel target and a novel idea for clinical prevention and treatment of diabetic nephropathy and improvement of renal lesions, and further proves that the improvement of renal oxidative stress plays an important role in the prevention and treatment of diabetic nephropathy.

The invention relates to a method for constructing a type II diabetes model by combining high-fat feeding with streptozotocin induction. According to the method, the high-fat and high-sugar diet is given by simulating the morbidity process of human type II diabetes, so that wide insulin resistance of mice is caused, but the blood sugar is not obviously increased. STZ is a powerful alkylating agentand can cause DNA alkylation, the DNA chain is broken, so that glycosylation of poly adenosinediphosphate ribose is activated, NO is released, the content of nicotinamide adenine in cells is rapidlyreduced, pancreatic beta cells are damaged or necrotic, insulin secretion is reduced, at the moment, most mice have abnormal glucose tolerance, and animal hyperglycemia is induced. The method has themain beneficial effects that the diabetes model of the female ICR mouse is successfully established through the research, and the pathological structure and biochemical detection change trend of the mouse are basically consistent with those of type II diabetes of human beings.

The invention provides medicine used for treating diabetes mellitus and complications thereof. The medicine is glycoprotein, or a mixture of polysaccharide and protein, or polypeptide or protein. The medicine has an obvious effect of reducing blood glucose of a rat diabetes model, and in the four weeks after the medicine is taken, the blood glucose of a rat is reduced from 27.06-27.19 mmol / L to 11.26-23.41 mmol / L. The medicine is used for treating diabetes mellitus continuously for four weeks, the result shows that a blood glucose value can be reduced obviously, the content of urine protein and the content of urea nitrogen in serum are reduced, the content of triglyceride in the serum is reduced, and the thymus indexes of the rat are increased. The medicine has the obvious effect of reducing the blood glucose and urine sugar of patients with the diabetes mellitus; meanwhile, the medicine has a function of adjusting hyperglycemia, hypertension, hyperlipidemia and high blood viscosity threatening the diabetes mellitus severely. The medicine has the advantages of being safe, efficient and free of side effects, and has the obvious effects of reducing the blood glucose, cholesterol and triglyceride.

The invention relates to a fusion gene GAD-GLP-1 and a culture method of diabetes diet therapy type cucumber. The fusion gene GAD-GLP-1 provided by the invention is shown as a sequence list, and comprises a section of glutamate decarboxylase gene GAD and a section of glucagon-like peptide-1 gene GLP-1, the glutamate decarboxylase gene GAD and the glucagon-like peptide-1 gene GLP-1 are connected through an EcoRV site, two lysines are respectively added at both sides of the EcoRV site, and the four amino acids simultaneously realize the effect of peptide connection. The invention is characterized in that the fusion gene in a cloning vector pMD-GAD-GLP-1 is connected into a Marker-free plant expression vector pX6 after the BamHI and SalI enzyme digestion recovery, a selective-marker-free plant expression vector pX6-GAD-GLP-1 is obtained through construction, and the selective-marker-free plant expression vector pX6-GAD-GLP-1 is converted into agrobacterium rhizogenes LBA4404 to be construction into engineered strains. The invention successfully converts the GAD-GLP-1 fusion gene into a cucumber self-bred line 2M1 by an agrobacterium rhizogenes mediate method, and obtains transgene plants of stably expressed GAD-GLP-1 fusion protein. Through the intragastric administration on diabetes model bandicoot of the transgene cucumber provided by the invention, the blood sugar level can be reduced, and the diabetes symptom can be relieved.

The invention discloses application of astragalin in preparation of a drug for treating diabetic testicular dysfunction. An experimental result shows that when the astragalin is used in a safety doserange, the dose is 30 mg / kg of astragalin, the astragalin can remarkably protect sperm injury induced by a diabetes model, improve pathologic change of testicular tissue, improve the oxidation resistance ability and regulate and control protein expression of inflammatory cytokines, and it is proved that the astragalin has the effect of improving the diabetic testicular dysfunction.

The invention provides a method for preparing bitter melon polypeptide with function of reducing blood sugar bioactivity by gene engineering and application. The method comprises construction, expression, purification and the like of an expression vector. The method can directionally, stably and effectively express the functional polypeptide with biological activity, and is favorable for industrialized production. Proved by animal experiments, the polypeptide prepared by the method can remarkably reduce the blood sugar value of a diabetes pattern animal, and can be used for preparing medicaments for preventing and treating diabetes.

The invention provides a construction method of a type I diabetes animal model. The method comprises the following steps: selecting C57BL / 6 mice, performing first tail vein injection, continuously performing intraperitoneal injection of a streptozotocin reagent for 5 days, performing ambrosia for 12 hours before injection, and allowing the mice to freely drink water. Two days after the injection procedure is completed, the ambrosia is carried out for 4 hours, and a glucometer is used for measuring blood glucose until the blood glucose value is 10 mmol / L or above. The statistical analysis of the blood glucose measurement result of the type I diabetes animal model shows that the C57BL / 6 mouse type I diabetes model constructed by using the streptozotocin is feasible and can be used for researching the diabetes pathogenesis and the anti-hyperglycemia intervention of medicaments and health-care foods. Compared with the prior art, the C57BL / 6 mouse type I diabetes model constructed by the invention has the advantages of high film forming rate, simple operation, no death of animals and good reproducibility.

The invention discloses a benzoic acid derivative as well as preparation and a hypoglycemic application thereof, the benzoic acid derivative is a compound represented by a formula I and a formula II, and in the formula I, R1 and R2 is any one of the following a)-d): a) R1=CH3, R2=COOH; b) R1=CH3, R2=COOCH3; c) R1=CH3, R2=CHO; and d) R1=CH2OH, R2=CH2OCH3; in the formula II, the R1 is any one of the following e)-g): e) R1=CH2CH2CH2COOH; f) R1=CH(COOH)CH(CH3)CH2CH3; and g) R1=CH(COOH)CH2(CH3)CH3. The experiment proves that the compound provided by the invention has strong activity for inhibiting alpha-glucosidase, and obviously reducing the blood glucose level of type II diabetes mellitus rat. The compound provided by the invention and the pharmaceutical salt thereof provide material basis for developing an innovative drug for treating and / or preventing type II diabetes mellitus, developing an innovative hypoglycemic drug for inhibiting alpha-glucosidase and developing food and functional healthcare products with above functions, and has potential huge social benefit and economic benefit.

The invention belongs to the technical field of testing or analyzing materials by means of chemical or physical properties of a measuring material, and discloses a method for measuring the regulationand control of Chemerin on insulin resistance and the intervention of a CMKLR1 agonist, which comprises the following steps: preparing a pancreatic diabetes model by adopting an arginine induction method, performing intraperitoneal injection of 350 mg / kg arginine once a day for 6 weeks, and establishing a pancreatic diabetes group by a mouse common diet; during the period, establishing a pancreas-derived diabetes mellitus group by the common diet of the mice;meanwhile, establishing a high-fat diet group by adopting a formula feed open diet; establishinga negative control group, wherein the mice are fed with ordinary diet and water for 6 weeks; adopting a general pathology, an enzyme-linked immunosorbent assay, a Real-Time PCR method and an intraperitoneal injection glucose tolerance test for detection; expressing all the detection data by mean plus or minus standard deviation, and testing the normal distribution is by Shapiro Wilk test; using single-factor variance analysis to comparegroups with each other, and if the groups do not conform to the normal distribution, using Mann-Whitney U test for comparison; significant difference lying in P < 0.05; applying SPSS 22.0 for Windowssoftware to implement the entire verification process.

The invention relates to application of a clam meat oligosaccharide in preparation of drugs or health foods for decreasing blood sugar and preventing and treating diabetes and a preparation method of the clam meat oligosaccharide. The optimized molecular weight range of the clam meat oligosaccharide is a 500-2000 clam meat oligosaccharide compound, and the total content is higher than 50 percent. Experimental results show that the clam meat oligosaccharide can significantly inhibit the blood sugar level and improve the glucose tolerance of model mice with alloxan-induced diabetes; the clam meat oligosaccharide has a significant effect of decreasing the blood sugar for mice with II type diabetes induced by high fat diet and STZ and the main expressions are as follows: the abnormal glucose tolerance of the mice with the II type diabetes is improved, the rise of plasma HbA1c is inhibited, the contents of hepatic glycogen and muscle glycogen are significantly increased, the utilization of hepatic glycogen is enhanced, the generation of glycogen is inhibited, the glucagon secretion is inhibited, the reserve of glycogen is enhanced, and the heteroplasia of sugar is reduced. Acute toxicity tests and researches show that the clam meat oligosaccharide has no toxic or side effects and is high in safety.

The invention belongs to the technical field of pharmaceutics. According to the invention, Jaceosidin can be used for remarkably improving mouse insulin resistance induced by high-fat diets, further improving mouse symptoms of the II-type diabetes mellitus models and remarkably improving the nonalcoholic fatty liver diseases and the chronic liver injury caused by the high-fat diets. The Jaceosidin serves as a novel medicine for treating insulin resistance, has activities of controlling blood glucose and improving insulin sensitivity and the like well, meanwhile, can be used for treating the nonalcoholic fatty liver diseases and is capable of effectively reducing liver fat pathological changes and chronic liver injury. Therefore, the Jaceosidin can be used for treating the insulin resistance, the nonalcoholic fatty liver diseases and the diseases related to II-type diabetes mellitus and preparing corresponding therapeutic medicines.